RxDoctor Payments Data

Young Kwak, MD

Internal Medicine · New Britain, CTNPI 1407182249

Payments from drug & device makers

$8,773in general payments, 2019–2025

Across 454 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$990
  • Novo Nordisk$791
  • Boehringer Ingelheim$742
  • AstraZeneca$699
  • Pfizer$646
  • Abbott$534
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,773100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,773 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$60,610
Medicare patients
249
Services billed
653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin158$258,697
EliquisApixaban137$191,121
OzempicSemaglutide103$181,344
JanuviaSitagliptin Phosphate41$67,904
XareltoRivaroxaban58$60,662
TrulicityDulaglutide31$57,216
MounjaroTirzepatide32$55,281
FarxigaDapagliflozin Propanediol28$41,826
RybelsusSemaglutide13$37,031
MyrbetriqMirabegron28$31,822
Trijardy XrEmpaglifloz/Linaglip/Metformin27$27,935
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$24,115
Synjardy XrEmpagliflozin/Metformin Hcl11$18,009
Mirabegron ErMirabegron13$9,434
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$8,193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Spiriva Respimat$742$312,507207 claims
Novo NordiskOzempic, Rybelsus$791$218,375116 claims
PfizerEliquis$646$191,121137 claims
Lilly USA, LLCTrulicity, Mounjaro$498$112,49763 claims
MerckJanuvia$293$67,90441 claims
Johnson & JohnsonXarelto$118$60,66258 claims
AstraZenecaFarxiga, Symbicort$699$47,91246 claims
Astellas Pharma US IncMyrbetriq$189$31,82228 claims
GSKTrelegy Ellipta$990$24,11521 claims
AbbVieSynthroid$427$4,78356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →